Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Nov;33(5):482-5.
doi: 10.1002/(sici)1096-911x(199911)33:5<482::aid-mpo8>3.0.co;2-y.

Cyclosporine A therapy for multisystem langerhans cell histiocytosis

M Minkov  1 , N Grois, V Broadbent, A Ceci, A Jakobson, S Ladisch
Affiliations
Clinical Trial

Cyclosporine A therapy for multisystem langerhans cell histiocytosis

M Minkov et al. Med Pediatr Oncol. 1999 Nov.

Abstract

Background: Treatment of multisystem Langerhans cell histiocytosis (LCH) remains difficult. Various regimens of single and multiagent chemotherapy have been used, but a significant proportion of patients fail to respond to treatment.

Procedure: We have evaluated the use of cyclosporine A (CSA) in a controlled group of patients, who had received a systematic primary therapy (LCH-I). Patients received CSA either as a single agent (10 patients) or in combination with vinblastine, etoposide, prednisolone, and/or antithymocyte globulin (16 patients).

Results: Among the total of 26 patients treated, a single patient developed a complete response and three a partial response, whereas 85% (22 patients) had no response to CSA.

Conclusions: CSA is at best of limited value in the treatment of patients with multisystem LCH, particularly those who had progressive disease while receiving chemotherapy.

PubMed Disclaimer

Publication types

LinkOut - more resources